August - 2022
| Previous Past Months | Showing Journal 4 of 4 |
Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery. The OPTIMAL Randomized Clinical TrialJ Shi, C Zhou, W Pan et al for the OPTIMAL Study Group JAMA, 2022, 328(4):336-347 This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
August |
Previous Comments
No Comments yet.
Comment
Tranexamic acid is the mainstay antifibrinolytic agent used to reduce blood loss after cardiac surgery. However there are ongoing concerns regarding associated seizures (increased risk of seizure, stroke, death at 1-year with single dose of 50 or 100 mg/kg in...